52 results about "Parabacteroides" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.

The invention discloses a meningioma enteric microbial marker, a product and application of the meningioma enteric microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized by being prepared from one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and is characterized in that the enteric microbial marker comprises one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and the enteric microbial marker comprises one or more of parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of meningioma, and provides a new tool for clinical diagnosis.

Provided are a Parabacteroides strain, a culture, a microbial agent and the use thereof. Specifically provided is a Parabacteroides strain, which can be a strain having a deposit number of GDMCC No: 62664 or 62665, or a strain having at least 96.74% identity to the 16S rRNA of the strain, and / or a strain having at least 87% average nucleotide identity to the genome of the strain. The strain or a product based on the strain has good effects in terms of preventing or treating tumors or cancers, metabolic diseases, inflammation or autoimmune diseases, infectious diseases and central nervous system diseases.

Provides *Parabacterium* strains, cultures, inoculants, and their applications. Specifically, provides a *Parabacterium* strain, which may be a strain with accession number GDMCC No: 62664 or 62665, or a strain with at least 96.74% identity to the strain's 16S rRNA and / or at least 87% average nucleotide identity to the strain's genome; the strain or products based on the strain have good preventive or therapeutic effects on tumors or cancers, metabolic diseases, inflammatory or autoimmune diseases, infectious diseases, and central nervous system diseases.

The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD). There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

The application discloses Paracoccus communis C4-4 and C5-3, the preservation number of which is CGMCC NO:31971 and the classification name of which is Paracoccus communis, and the preservation number of which is CGMCC NO:31972 and the classification name of which is Paracoccus communis. Researches show that C4-4 and C5-3 have strong ecological adaptability and good growth promotion ability, and can improve the internal environment of soil in combination with organic materials. A synthetic microbial population constructed by Paracoccus communis comprises C4-4 and C5-3. Tests prove that the synthetic microbial population comprising C4-4 and C5-3 has the advantages of the synthetic microbial population, the microbial population has high alkali production and growth promotion ability, has good ecological adaptability, the pH adaptation range is 4-8, the manganese stress tolerance can reach 5000 μmol / L, can significantly improve the pH of a culture medium, and has obvious alkalization effect. The synthetic microbial population is used as a microbial agent and is compounded with organic materials to prepare a soil conditioner capable of improving acid soil and promoting plant growth. The conditioner is applied to acid and lean soil, can significantly improve the soil pH, improve the content of soil organic matter, nitrogen, phosphorus and potassium, and promote root growth.

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

The invention belongs to the field of biological medicine, and discloses application of parabacteroides dieldrii in preparation of an osteoporosis improving agent. The research of the inventor finds that after the parabacteroides dieldrii is supplemented through intragastric administration, the proportion of Th17 cells can be reduced, secretion of IL-17 and TNF-alpha can be reduced, and the activity of osteoclasts can be inhibited; according to the present invention, with the application of the parabacteroides dieldrii in the preparation of the oral liquid, the osteoporosis can be effectively improved by adding the parabacteroides dieldrii in the stomach, the osteoporosis can be effectively improved, the osteoporosis can be effectively improved, and the great application prospect can be provided, and the effects of the oral liquid such as the intestinal tract, the intestinal tract flora structure, the probiotic (such as the bifidobacterium and the lactobacillus), and the osteoporosis can be effectively improved can be provided.

The invention discloses an application of parabacteroides dieldrii in preparation of a product for treating hyperuricemia. The activity of xanthine oxidase is inhibited through the parabacteroides dieldrii, uric acid related transporters are changed, and damaged organs are protected to play a uric acid reducing effect, so that chronic hyperuricemia is improved. In vitro, the parabacteroides dieldrii can inhibit the activity of xanthine oxidase. On the animal level, the parabacteroides dielsii can relieve liver and kidney injuries caused by hyperuricemia and can repair the injured intestinal barrier at the same time. Therefore, a design thought can be provided for an intestinal flora uric acid reducing preparation, so that a new intestinal flora target is provided for clinical treatment of hyperuricemia. According to the present invention, the activity of xanthine oxidase is inhibited in vitro, the uric acid transporter URAT1 in the kidney is reduced in vivo, the uric acid excretion transporter ABCG2 is increased, and the liver and kidney injury and the intestinal barrier damage caused by hyperuricemia are relieved so as to reduce the serum uric acid level and improve the hyperuricemia;

To provide a composition that increases the occupancy rate of bacterium of the genus Parabacteroides and bacterium of the genus Bifidobacterium in intestinal flora.SOLUTION: A composition for improving intestinal flora is provided, the composition containing any one material selected from trehalulose, isomaltulose, turanose, maltulose, and oligosaccharides containing any one material from these materials as a constituent sugar.SELECTED DRAWING: Figure 1

The invention discloses a preparation method and application of edible fungus polysaccharide capable of effectively promoting proliferation of Parabacteroides in human intestinal tracts, and belongs to the technical field of extraction of edible fungus polysaccharide. The method comprises the following steps: carrying out enzymolysis on Schizophyllumcommuneh sporocarp through a compound enzyme, then carrying out ultrasonic-assisted extraction on enzymatic hydrolysate, carrying out evaporation concentration on the obtained extract, then carrying out Co 60 gamma-irradiation treatment, further carrying out enzymolysis through papain after irradiation is completed, repeatedly freezing and thawing the enzymatic hydrolysate for 2-3 times, then carrying out ethanol precipitation, and drying to obtain the Schizophyllumcommuneh polysaccharide. The Schizophyllumcommuneh polysaccharide prepared by the method is small in molecular weight and high in solubility, can remarkably promote proliferation of paracterobacter, can be used as an ingredient of functional food, and is of great significance to development of functional products for directional regulation and control of intestinal flora.

The invention discloses parabacteroides faecalis PM01 and application thereof in preparation of drugs for treating or preventing diabetes mellitus, and belongs to the technical field of microorganisms. The preservation number of the parabacteroides faecalis PM01 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 22983. The parabacteroides faecalis PM01 has a relatively strong effect of inhibiting alpha-glucosidase in vitro, can remarkably reduce the in-vivo glucose content of a zebra fish hyperglycemia model in vivo, and has the potential of being applied to in-vivo blood glucose level regulation; the invention provides a theoretical reference and a guidance basis for developing a probiotic preparation for preventing or treating diabetes mellitus by utilizing the parabacteroides faecalis PM01.

Provided herein are compositions comprising in vivo succinate-producting microorganisms, e.g., Bacteroides and Prevotella species (preferably Bacteroides thetaiotaomicron (e.g., VPI 5482), Bacteroides vulgatus (e.g., NCTC 11154, Prevotella copri (e.g., DSM 18205)), Parabacteroides (e.g., Parabacteroides distasonis), and Bacilli (e.g. Lactobacillus animalis), and methods of use thereof in treating or reducing risk of developing an intestinal infection, optionally an infection with Campylobacter, Salmonella, E. coli, Shigella, Listeria monocytogenes, Vibrio, Enteropathogenic E. coli, Klebsiella, or Clostridioides difficile, or promoting expansion of colonic tuft cells, in a subject.

The invention discloses a primer composition for detecting bifidobacterium bifidum of which the microbial preservation number is CCTCC (China Center for Type Culture Collection) NO: M2023349, enterococcus avium of which the microbial preservation number is CCTCC NO: M2023350, lactobacillus salivarius of which the microbial preservation number is CCTCC NO: M2023348, lactobacillus fermentum of which the microbial preservation number is CCTCC NO: M2023352, and parabacteroides didysonii of which the microbial preservation number is CCTCC NO: M20222033. The invention further discloses a kit based on the primer composition and application of the kit. The primer composition has good specificity and high accuracy aiming at the five bacteria, and can detect the five bacteria in a complex environment to evaluate the physiological status of a subject.

The present invention discloses Parabacteroides distasonis NSP007 for alleviating insulin resistance and its application, belonging to the field of microbial technology. Parabacteroides distasonis NSP007 of the present invention can inhibit the weight gain and body fat accumulation of IR mice without affecting food intake; improve the glucose tolerance and insulin sensitivity of IR mice, while reducing the serum insulin and insulin resistance index of mice; regulate the lipid metabolism disorder of IR mice and relieve liver tissue damage; improve the intestinal barrier function of IR mice. The Parabacteroides distasonis NSP007 of the present invention is used for preparing a pharmaceutical composition for alleviating IR, and has very broad application prospects.

The invention discloses an application of parabacteroides faecalis PM01 in preparation of drugs for preventing or treating inflammatory diseases, and belongs to the technical field of microorganisms. According to the application of the parabacteroides faecalis PM01 in preparation of the medicine for preventing or treating the inflammatory diseases, the parabacteroides faecalis PM01 can inhibit neutrophil and macrophage from gathering towards the inflammation position of the tail fin of zebra fish in an in-vivo inflammation model; the parabacteroides faecalis PM01 can be used for inhibiting the increase of the content of LPS-induced inflammatory factors IL-1beta, IL-6 and TNF-alpha (Tumor Necrosis Factor-alpha); theoretical reference and guidance basis are provided for developing medicines for preventing or treating inflammatory diseases by utilizing the parabacteroides faecalis PM01.

To find out a useful living body-regulating function in a treated product of Abelmoschus manihot and to provide a functional use thereof.SOLUTION: An intestinal environment-improving agent comprising a processed product of Abutilon striata as an active ingredient, wherein the intestinal environment-improving agent increases bacteria of the genus Lactobacillusmurinus and / or the genus Parabacteroides.SELECTED DRAWING: Figure 5

There is provided bacterial compositions for treatment of bipolar disorder or symptoms thereof and methods of treating bipolar disorders or symptoms there of using the same. The compositions comprise a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides.

The invention discloses a parabacteroides strain, a culture, a fungicide and application of the parabacteroides strain, the culture and the fungicide. In a first aspect of the present application, a strain of the genus Parabacteroides is provided, which can be a strain having a preservation number GDMCC No: 62664 or 62665, or a strain having at least 96.74% identity to the 16S rRNA of the strain, and / or having at least 87% average nucleotide identity to the genome of the strain. According to the embodiment of the invention, a new strain under parabacteroides is newly found, and the strain or a product based on the strain has good effects of preventing or treating tumors or cancers, metabolic diseases, inflammations or autoimmune diseases, infectious diseases and central nervous system diseases.

Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

The invention belongs to the field of biological medicine, and particularly relates to application of a fluorinated quinoline derivative in inhibition of colon cancer pathogenic bacteria. The invention firstly provides a fluorinated quinoline derivative or a pharmaceutical salt thereof; the fluorinated quinoline derivative can inhibit fusobacterium nucleatum, has no inhibition effect on common intestinal bacteria such as bifidobacterium animalis subsp. Lactis, mucophilic protein-ackermania, bacteroides multiforme, clostridium sporogenes, lactobacillus reuteri, parabacteroides dielsii and the like, and has the characteristics of good fusobacterium nucleatum resistance activity and specificity; the fusobacterium nucleatum can be used for treating diseases caused by fusobacterium nucleatum infection.

The invention provides application of parabacteroides dieldrii in preparation of a medicine for treating Parkinson's disease. The parabacteroides dieldrii can play a neuroprotective role through multiple mechanisms of regulating intestinal flora, reducing neuroinflammation, improving a blood-brain barrier function and the like. Animal experiments show that the active parabacteroides dielsii can significantly improve PD mouse dyskinesia, protect dopaminergic neurons, repair intestinal and central barriers, and remodel a metabolite spectrum related to nerve regulation. The intestinal symbiotic bacterium parabacteroides dieldrii provided by the invention has a good effect of treating the Parkinson's disease, and has a wide application prospect in the field of micro-ecological treatment of the Parkinson's disease.

The invention discloses application of parabacteroides dieldrii in preparation of a medicine for treating prostatic cancer, and belongs to the field of biological medicine. It is found for the first time that the abundance of parabacteroides dieldrii in intestinal flora of a prostate cancer patient is remarkably reduced, and the parabacteroides dieldrii is selected as potential probiotics for inhibiting growth of prostate cancer tumors. The result of a parabacteroides dieldrii single bacterium colonization experiment shows that the parabacteroides dieldrii and the metabolite gamma-linolenic acid (GLA) thereof can efficiently inhibit the growth of the prostatic cancer tumor, can also improve the condition that the treatment effect of docetaxel on the prostatic cancer is poor due to abuse of clinical antibiotics, and can be prepared into the medicine for treating or assisting in treating the prostatic cancer. The invention provides a new treatment strategy and medicine for the treatment of the prostatic cancer, and also provides a brand new medicine development path and a clinical application scheme for the micro-ecological treatment of the prostatic cancer.

The invention relates to application of parabacteroides faecalis in preparation of a medicine for treating graft-versus-host disease. According to the invention, parabacteroides faecalis is used as a single strain for coprophilous fungus transplantation to treat intestinal GVHD. The P.Merde not only shows the effect of inhibiting allogeneic T cell proliferation and inflammatory response in vitro and in animal models, but also can significantly improve the survival rate and intestinal microenvironment of GVHD mice. Compared with traditional FMT, P.Merde treatment of a single strain has the advantages of being clear in component, capable of being standardized, low in risk and the like, and shows a good application prospect.

The invention belongs to the technical field of biology, and particularly relates to an antibacterial peptide capable of improving animal intestinal health and resisting diarrhea and a preparation method thereof.The novel antibacterial peptide is prepared, and the amino acid sequence of the novel antibacterial peptide is shown as SEQ ID NO: 1; experiments prove that after the cat is raised in a strange environment for one week, the antibacterial peptide can slightly improve the propionic acid and butyric acid levels of the experimental group cat; and the total BCFAs level of the experimental group before and after transportation is lower than that of the blank group. Although the alpha diversity and the beta diversity between an experimental group fed with the antibacterial peptide and a blank group have no significant difference, the feeding of the antibacterial peptide significantly increases the levels of bacteroides, parabacteroides and paraprevotella in the experimental group, and significantly reduces the levels of harmful bacteria such as salmonella and actinomycetes. Therefore, the antibacterial peptide disclosed by the invention can be used for preparing products for improving animal intestinal health and resisting diarrhea, such as feed additives or oral liquid.

The invention discloses an application of parabacteroides gore outer membrane vesicles in preparation of drugs for neuroprotection and / or anxiety disorder improvement. Researches show that the parabacteroides gore outer membrane vesicles can effectively antagonize corticosterone-induced nerve cell injury, can relieve anxiety-like behaviors of chronic constraint stress mice, and have good neuroprotection and anxiety-resistant activity. The invention provides a new drug choice for clinically treating nerve injury and relieving anxiety disorder, and has a wide application prospect in the aspect of treating nervous system diseases.

The invention discloses application of parabacteroides dieldrii in preparation of a medicine for improving CKD sarcopenia, and belongs to the technical field of microorganisms. According to the application, blood-targeted metabonomics, fecal metagenomics, muscle-targeted metabonomics and muscle transcriptomics detection and analysis are carried out on a constructed CKD model mouse, and it is found that bile acid and lipid metabolism abnormalities exist in muscle tissues of the CKD sarcopenia mouse; in combination with metagenomics, it is further found that the parabacteroides dieldrii in the intestinal flora of the mouse is closely associated with metabolism of the parabacteroides dieldrii and the intestinal flora of the mouse. After the parabacteroides dieldrii is supplemented into the CKD model mouse body, the expression levels of bile acid and lipid metabolism related receptors can be intervened, so that the metabolism of the bile acid and lipid metabolism related receptors is improved, and the muscle quality of the mouse is obviously improved. In conclusion, the invention provides the new application of the parabacteroides dieldrii in preparing the medicine for improving the CKD sarcopenia.

Provided is a composition for promoting the proliferation of the genus Parabacteroides, the composition containing any substance selected from sugar acid-containing oligosaccharides and salts thereof. The sugar acid-containing oligosaccharide is preferably maltobionic acid or lactobionic acid.

The invention provides application of parabacteroides dielsii-derived outer membrane vesicles in acute rejection of heart transplantation, and belongs to the technical field of biological medicines. The invention provides the application of the outer membrane vesicles derived from the parabacteroides dieldrii in preparation of the medicine for relieving acute rejection of heart transplantation, and the outer membrane vesicles derived from the parabacteroides dieldrii have good biocompatibility and immune negative regulation capability, can effectively relieve acute rejection of organ transplantation immune, and can be used for preparing the medicine for relieving acute rejection of heart transplantation. The toxic and side effects caused by long-term use of the immunosuppressor are reduced, a new thought and scheme are provided for the development of the novel immunosuppressor, and the application prospect is wide.

The invention relates to the technical field of microorganisms, in particular to a parabacteroides dieldrii freeze-dried microecological preparation and an industrial fermentation culture method. A freeze-drying protective additive adopted in the preparation process of the freeze-dried microecological preparation of the parabacteroides dielsii contains trehalose, cane sugar, maltodextrin, glycerol and cysteine. The number of viable bacteria in the freeze-dried microecological preparation of the parabacteroides dieldrii prepared by adopting the freeze-drying protective agent is the largest. Meanwhile, the invention develops a set of industrial large-scale fermentation culture method suitable for the parabacteroides dieldrii, and a key process parameter system is established, so that efficient, stable and reproducible industrial production is realized. The application and popularization of the parabacteroides dieldrii in micro-ecological feed additives can be supported, a solid technical foundation is provided for commercialization of the parabacteroides dieldrii in the field of micro-ecological preparations for ruminants, and meanwhile, the method has reference significance for industrial production process development of other anaerobic probiotics.